The Critical Care Research team is currently participating in the following clinical trials. Please click on the name of the trial to see the study summary:
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients.
WSA-CS-008: A Phase III, Double- Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections.
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with Complicated Urinary Tract Infection.
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Blood Stream Infections due to Staphylococci.
Immune Response to Viral Infection.
Immune Responses Induced by Different Manufacturers of Influenza Vaccines.
Determination of Bromide Elimination Rate in Cystic Fibrosis (CF) Patients and Healthy Controls.
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors (Protocol # CFFC-OB-11).
A Phase 3, Randomized Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Subjects with Cystic Fibrosis. Protocol Number: GS-US-205-0170.
A Phase 3, Randomized, Double‑Blind, Placebo‑Controlled, Parallel‑Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del‑CFTR Mutation – Protocol Number VX-809-104